Public Health Scotland. (2023) National benchmarking report on implementation of the medication assisted treatment (MAT) standards: Scotland 2022/2023. Edinburgh: Public Health Scotland.
Preview | Title | Contact |
---|---|---|
|
PDF (National benchmarking report on implementation of MAT standards 2022-23)
18MB |
This release by Public Health Scotland (PHS) is a benchmarking report on the progress that Alcohol and Drug Partnerships (ADPs) in Scotland are making to meet the medication assisted treatment (MAT) standards. The report includes recommended actions to address gaps.
Main points
- MAT standards 1–10 were assessed across all 29 ADPs using a 'red, amber, green, blue' (RAGB) status.
- For standards 1–5, 66% (96/145) are fully implemented (19/145, 13% green; 77/145, 53% provisional green) vs. 17% (25/145) in 2022 (Chart 1).
- For standards 6–10, 88% (127/145) are partially implemented (65/145, 45% amber; 62/145, 43% provisional amber) and 12% (18/145) are not implemented (Chart 2).
- This demonstrates substantial progress with implementation of the MAT standards throughout the ADP areas, but there is still a lot to do for full, consistent and sustained implementation of the standards across Scotland.
Item Type
Report
Publication Type
International, Report
Drug Type
Substances (not alcohol/tobacco), Opioid
Intervention Type
Treatment method
Date
20 June 2023
Pages
190 p.
Publisher
Public Health Scotland
Corporate Creators
Public Health Scotland
Place of Publication
Edinburgh
EndNote
Related (external) link
Subjects
B Substances > Opioids (opiates)
B Substances > Opioids (opiates) > Opioid product > Buprenorphine / Suboxone
B Substances > Opioids (opiates) > Opioid product > Methadone
HJ Treatment or recovery method > Substance disorder treatment method > Substance replacement method (substitution)
HJ Treatment or recovery method > Substance disorder treatment method > Substance replacement method (substitution) > Opioid agonist treatment (methadone maintenance / buprenorphine)
J Health care, prevention, harm reduction and treatment > Treatment and maintenance > Treatment factors
MP-MR Policy, planning, economics, work and social services > Programme planning, implementation, and evaluation > Quality standards
VA Geographic area > Europe > United Kingdom > Scotland
B Substances > Opioids (opiates) > Opioid product > Buprenorphine / Suboxone
B Substances > Opioids (opiates) > Opioid product > Methadone
HJ Treatment or recovery method > Substance disorder treatment method > Substance replacement method (substitution)
HJ Treatment or recovery method > Substance disorder treatment method > Substance replacement method (substitution) > Opioid agonist treatment (methadone maintenance / buprenorphine)
J Health care, prevention, harm reduction and treatment > Treatment and maintenance > Treatment factors
MP-MR Policy, planning, economics, work and social services > Programme planning, implementation, and evaluation > Quality standards
VA Geographic area > Europe > United Kingdom > Scotland
Repository Staff Only: item control page